Showing results (161-170 of 185) with videos related to

Sort By:
Pageof 19
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Blood Advances|October 14, 2021
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemiaGiovanni Martinelli, Cristina Papayannidis, Alfonso Piciocchi, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Blood Advances|April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohortAndrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Blood|January 4, 2019
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactPanagiotis Baliakas, Sabine Jeromin, Michalis Iskas, et al.
Haematologica|April 21, 2018
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM studyAntonio Cuneo, George Follows, Gian Matteo Rigolin, et al.
Cancers|January 11, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 StudyFrancesca Romana Mauro, Francesca Paoloni, Stefano Molica, et al.
Cancers|March 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE StudyFrancesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Pageof 19